Migergot Suppository
Product Images NDC 0713-0166

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Migergot (NDC 0713-0166). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cosette Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Maximum Adult Dosage: One Suppository At Start Of Attack; Second Suppository After 1 Hour, If Needed For Full Relief. Early Administration Gives Maximum Effectiveness. (0166administration)

This text appears to be a set of instructions for using suppositories to relieve an undefined ailment. The recommended dosage for adults is not clear, and there is a suggestion that a second suppository should be used if needed, after one hour. Administration is recommended rectally, and the instructions suggest that early administration is important for maximum effectiveness.*

FDA Label Image

Carton Label For Migergot®, Ergotamine Tartrate And Caffeine Suppositories Usp 12 Count (0166cartonlabel)

FDA Label Image

0166foil Back

This text does not provide enough information to generate a useful description as it consists of random characters and symbols. The text is likely a result of a low-quality scan.*

FDA Label Image

0166foil Front

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.